Radius Bubbles Through Three CEOs, As Osteoporosis Drug Delayed
Published: Dec 20, 2013
Radius Health’s skin patch for osteoporosis appears to have fallen short of expectations in a mid-stage clinical trial, leading to a roughly two-year delay in development and what’s been a revolving door of four CEO’s over the past month, Xconomy has learned. The Cambridge, MA-based company, which tried to go public last year, but ultimately withdrew its IPO application, has pinned much of its hope on a skin patch treatment for osteoporosis that could be an alternative to regular injections. The key test of this technology came this year in a 250-patient clinical trial that ended in August, and yielded data for the company before the end of September.
Help employers find you! Check out all the jobs and post your resume.